Post-Introduction Evaluation (PIE) of Covid-19 Vaccination in Delhi: Application of WHO Framework
Main Article Content
Abstract
The present study was undertaken for the Post-Introduction Evaluation (PIE) of COVID-19 vaccination across different levels of healthcare system in Delhi. It was conducted in accordance with the guideline provided in the WHO PIE tool to assess the COVID-19 vaccine introduction and document strength and weaknesses. The study found that The detailed operational plans were available at state, district and health facility levels. Both electronic and paper-based reporting and recording mechanism were deployed for COVID-19 vaccination. There was neither stock out nor expiry reported for COVID-19 vaccine. There was an AEFI committee functional with availability of a system and written protocol for monitoring and reporting of AEFIs of COVID-19 vaccine
Downloads
Article Details
Section
How to Cite
References
1. World Health Organization. New Vaccine Post-Introduction Evaluation (PIE) Tool. Geneva: World Health Organization:2010. https://iris.who.int/bitstream/handle/10665/70436/WHO_IVB_10.03_eng.pdf (Accessed on 25-03-2025)
2. World Health Organization. COVID-19 vaccine post-introduction evaluation (cPIE). Geneva, Switzerland: World Health Organization; 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-cPIE-2021.1 (Accessed on 25-03-2025)
3. Ministry of Health and Family Welfare, Government of India. COVID-19 Vaccination India begins World’s Largest Vaccination Drive on 16 January [Internet]. 2021. Available from: https://www.pib.gov.in/PressReleasePage.aspx?PRID=1689112 (Accessed on 25-03-2025)
4. Government of India. Revised Guidelines for implementation of National COVID Vaccination Program. New Delhi: Ministry of Health and Family Welfare, Government of India; 2021. Available from: https://covid19.india.gov.in/document/revised-guidelines-for-implementation-of-national-covid-vaccination-program/ (Accessed on 25-03-2025)
5. Government of India. COVID-19 Vaccines, Operational Guidelines December 2020. New Delhi: Ministry of Health and Family Welfare, Government of India. 2020. https://covid19dashboard.mohfw.gov.in/pdf/COVID19VaccineOG111Chapter16.pdf (Accessed on 25-03-2025)
6. Lahariya C, Paruthi R, Bhattacharya M. How a New Health Intervention Affects the Health Systems? Learnings from Pentavalent Vaccine Introduction in India. The Indian Journal of Pediatrics. 2015;83(4):294-299. DOI: https://doi.org/10.1007/s12098-015-1844-x
7. Ahmed D, VanderEnde K, Harvey P, et al. Human papillomavirus (HPV) vaccine introduction in Sikkim state: Best practices from the first statewide multiple-age cohort HPV vaccine introduction in India-2018-2019. Vaccine. 2022;40 Suppl 1(Suppl 1):A17-A25. DOI: https://doi.org/10.1016/j.vaccine.2021.07.024
8. Chowdhury AK, Roy T, Faroque AB, Bachar SC, Asaduzzaman M, Nasrin N. et al. A comprehensive situation assessment of injection practices in primary health care hospitals in Bangladesh. BMC Public Health. 2011 Oct 10;11:779. DOI: https://doi.org/10.1186/1471-2458-11-779
9. Joshi J, Das MK, Polpakara D, Aneja S, Agarwal M, Arora NK. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India. Indian J Pediatr. 2018;85(2):139-148. DOI: https://doi.org/10.1007/s12098-017-2532-9
10. Mittal S, Rawat C, Gupta A, Solanki HK, Singh RK. Adverse Events Following Immunization Among Children Under Two Years of Age: A Prospective Observational Study From North India. Cureus. 2023;15(4):e38356. DOI: https://doi.org/10.7759/cureus.38356
11. National Institute of Epidemiology, Indian Council of Medical Research. Report of Programme Implementation Review following Rotavirus vaccine introduction in India - A Rapid assessment. Chennai, India: National Institute of Epidemiology, Indian Council of Medical Research; 2016. Available from: http://www.icmr.nic.in . (Accessed on 25-03-2025)
12. World Health Organization. Report of the post introduction evaluation of Haemophilus influenza type b (Hib) as pentavalent (DPT + HepB + _Hib) vaccine in Tamil Nadu and Kerala, India, 2012. New Delhi: World Health Organization Country Office for India; 2012.
13. Malik A, Haldar P, Ray A, Shet A, Kapuria B, Bhadana S. et al. Introducing rotavirus vaccine in the Universal Immunization Programme in India: From evidence to policy to implementation. Vaccine. 2019 Sep 16;37(39):5817-5824. DOI: https://doi.org/10.1016/j.vaccine.2019.07.104
14. World Health Organization. Post-Introduction Evaluation (PIE) of Pentavalent (DTP-Hib-Hepatitis B) and Inactivated Polio Vaccines. New Delhi: World Health Organization, Regional office for South East Asia; 2017 https://iris.who.int/bitstream/handle/10665/272402/sea-immun-111.pdf?sequence=1&isAllowed=y (Accessed on 25-03-2025)
15. Lahariya C, Subramanya B P, Sosler S. An assessment of hepatitis B vaccine introduction in India: Lessons for roll out and scale up of new vaccines in immunization programs. Indian Journal of Public Health 2013;57(1):8-14 DOI: https://doi.org/10.4103/0019-557X.111357
16. World Health Organization. Post-Introduction Evaluation of Pentavalent Vaccine and Measles-containing Vaccine Second dose in Goa, Gujarat, Haryana, Jammu and Kashmir, Karnataka and Puducherry. New Delhi: World Health Organization, Country Office for India; 2014.